InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update
InspireMD(NSPR) GlobeNewswire News Room·2024-08-06 20:09- Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any carotid stent or embolic protection device pivotal trial – - On track to submit a Premarket Approval (PMA) application to the FDA this quarter - - Raised gross proceeds of $17.9 million from full exercise of Series H warrants triggered by announcement of C-GUARDIANS data - -- Management to host investor conference ca ...